These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1718374)

  • 1. New anticancer agents.
    Brown TD; Burris HA; Havlin KA; O'Rourke TJ; Rodriguez GI; Wall JG; Weiss GR
    Cancer Chemother Biol Response Modif; 1991; 12():111-46. PubMed ID: 1718374
    [No Abstract]   [Full Text] [Related]  

  • 2. New anticancer agents.
    Weiss GR; Arteaga CL; Brown TD; Craig JB; Harman GS; Havlin KA; Koeller JM; Kuhn JG; Von Hoff DD
    Cancer Chemother Biol Response Modif; 1988; 10():85-116. PubMed ID: 2484323
    [No Abstract]   [Full Text] [Related]  

  • 3. New anticancer agents.
    Weiss GR; Arteaga CL; Brown TD; Craig JB; Harman GS; Koeller JM; Kuhn JG; Von Hoff DD
    Cancer Chemother Biol Response Modif; 1987; 9():93-120. PubMed ID: 2484330
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel chemotherapeutic agents in early clinical development.
    Stagg MP; Diasio RB
    Curr Opin Oncol; 1990 Dec; 2(6):1119-25. PubMed ID: 1983089
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice.
    Sternberg CN; Sordillo PP; Cheng E; Chuang YJ; Niedzwiecki D
    Am J Clin Oncol; 1987 Jun; 10(3):219-21. PubMed ID: 2884864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anthracycline antitumor antibiotics.
    Muggia FM; Green MD
    Crit Rev Oncol Hematol; 1991; 11(1):43-64. PubMed ID: 1831987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer.
    Boven E; Schlüper HM; Erkelens CA; Pinedo HM
    Eur J Cancer; 1990; 26(9):983-6. PubMed ID: 2149026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline analogs: the past, present, and future.
    Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
    Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of clinical results of new antitumor drugs].
    Ogawa M
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biochemical pharmacology of nogalamycin and its derivatives.
    Li LH; Krueger WC
    Pharmacol Ther; 1991; 51(2):239-55. PubMed ID: 1838416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of oral menogaril administered daily for 14 consecutive days.
    Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
    Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Brown TD; Goodman PJ; Fleming TR; Baker LH; Macdonald JS
    Invest New Drugs; 1991 Feb; 9(1):77-8. PubMed ID: 1827433
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of menogaril in advanced malignant melanoma. An EORTC trial.
    Gundersen S; Monfardini S; Renard G; Van Glabbeke M; Pinedo H
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1707-8. PubMed ID: 2962875
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial.
    Locker GY; Kilton L; Hoeltgen T; Knop RH; Benson AB; Chernicoff D; Barrett J; Blough R; Johnson C
    Cancer Treat Rep; 1987 Sep; 71(9):871-2. PubMed ID: 2957053
    [No Abstract]   [Full Text] [Related]  

  • 16. Negative phase II trial of menogaril in advanced squamous, adeno- and large cell carcinoma of the lung.
    Joss RA; Monfardini S; Hansen M; Dombernowsky P; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1988 Feb; 24(2):263-5. PubMed ID: 2833403
    [No Abstract]   [Full Text] [Related]  

  • 17. The development of new chemotherapeutic agents.
    Hanauske AR
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():29-32. PubMed ID: 8862708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of menogaril in patients with advanced hypernephroma.
    Long HJ; Hauge MD; Therneau TM; Buckner JC; Frytak S; Hahn RG
    Invest New Drugs; 1991 Aug; 9(3):261-2. PubMed ID: 1838363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menogaril in the treatment of malignant mesothelioma: a phase II study.
    Hudis CA; Kelsen DP
    Invest New Drugs; 1992 Jul; 10(2):103-6. PubMed ID: 1386842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.